Guided Therapeutics to Present at 2015 Aegis Growth Conference

NORCROSS, Ga.–(BUSINESS WIRE)–Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid, point of
care cervical cancer testing platform based on its patented biophotonic
technology, announced today that it will be presenting at the 2015 Aegis
Growth Conference to be held October 7-9, 2015 at the Encore at Wynn Las
Vegas, Las Vegas, NV.

Event: 2015 Aegis Growth Conference
Location: The Encore at Wynn Las Vegas
Date: October 8, 2015
Time: 2:00 PM (PST)

Guided Therapeutics’ Chief Executive Officer, Gene Cartwright, will
deliver the Company’s corporate presentation and discuss recent business
highlights. Mr. Cartwright will also be available for one-on-one
meetings.

To arrange a meeting with management, please contact Robert Haag at gthp@irthcommunications.com
or on 1-866-976-4784.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and
painless testing platform based on its patented biophotonic technology
that utilizes light for the early detection of disease at the cellular
level. The Company’s first product is the LuViva® Advanced
Cervical Scan, a non-invasive device used to detect cervical disease
instantly and at the point of care. In a multi-center clinical trial,
with women at risk for cervical disease, the technology was able to
detect cervical cancer up to two years earlier than conventional
modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced
Cervical Scan is an investigational device and is limited by federal law
to investigational use in the U.S. LuViva, the wave logo and “Early
detection, better outcomes” are registered trademarks owned by Guided
Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and
subject areas discussed in this news release that are not historical or
current facts deal with potential future circumstances and developments.
The discussion of such matters and subject areas is qualified by the
inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from Guided Therapeutics’
actual future experience involving any of or more of such matters and
subject areas. Such risks and uncertainties include those related to the
early stage of products in development, the uncertainty of market
acceptance of products, the uncertainty of development or effectiveness
of distribution channels, the intense competition in the medical device
industry, the sufficiency of capital raised in our prior financings and
our ability to realize their expected benefits, the uncertainty of
future capital to develop products or continue as a going concern, the
uncertainty of regulatory approval of products, and the dependence on
licensed intellectual property, as well as those that are more fully
described from time to time under the heading “Risk Factors” in Guided
Therapeutics’ reports filed with the SEC, including Guided Therapeutics’
Annual Report on Form 10-K for the fiscal year ended December 31, 2014
and subsequent filings.

Contacts

Investor and Media Relations Contact:
IRTH Communications
Robert
Haag, 866-976-4784
Managing Partner
GTHP@irthcommunications.com
or
Guided
Therapeutics
Bill Wells, 770-242-8723